20 November 2026

Results of Annual General Meeting

Argent BioPharma would like to announce the results from the Company's Annual General Meeting of Shareholders held today, Friday, 20 November 2026, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

—Ends—

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating specialty biopharmaceutical company focused on building a differentiated immune-modulation intellectual property platform through the development, commercialisation and strategic licensing of innovative therapeutics.

The Company's portfolio is anchored by CimetrA®, its lead immune-modulation platform targeting inflammatory and autoimmune diseases, supported by next-generation NanoBodies and peptide technologies, proprietary drug delivery systems and pharmaceutical manufacturing capabilities.

Argent BioPharma's strategy combines intellectual property ownership, focused pharmaceutical development, manufacturing and strategic licensing, allowing the Company to monetise mature and non-core assets while concentrating internal resources on the development of its core immune-modulation portfolio.

Results of meeting

Listing Rule 3.13.2

Name of entity

Argent Biopharma Limited

ABN/ACN/ARSN/ARBN

116 800 269

Date of meeting

20 November 2026

Resolutions voted on at the meeting					If decided by poll/valid					Proxies received			
Resolution		Result	Voting method	If s250U	For		Against		Abstained	For	Against	Abstain	Discretion
No	Short description				Number	%	Number	%	Number	Number	Number	Number	Number
1	Adoption of Remuneration Report	Passed	Poll	N/A	26,374,631	99.33%	178,510	0.67%	6,028,358	25,924,172	178,510	6,028,358	450,459
2	Election of Director – Andrew Chapman	Passed	Poll	N/A	46,899,950	99.62%	176,762	0.38%	6,004,787	46,449,491	176,762	6,004,787	450,459
3	Re-election of Director – Roby Zomer	Passed	Poll	N/A	46,895,132	99.61%	182,019	0.39%	6,004,348	46,444,673	182,019	6,004,348	450,459
4	Ratification of Prior Issue of Convertible Notes	Passed	Poll	N/A	46,958,185	99.75%	116,184	0.25%	6,007,130	46,507,726	116,184	6,007,130	450,459
5	Ratification of Prior Issue of Advisory Options	Passed	Poll	N/A	46,864,847	99.55%	209,946	0.45%	6,006,706	46,413,853	209,946	6,006,706	450,994
6	Approval to Issue Options – July Drawdown	Passed	Poll	N/A	46,891,629	99.61%	185,442	0.39%	6,004,428	46,441,170	185,442	6,004,428	450,459
7	Approval to Issue Convertible Notes and Options – August Drawdown	Passed	Poll	N/A	46,866,107	99.55%	210,984	0.45%	6,004,408	46,415,614	210,984	6,004,408	450,493
8	Approval to Issue Convertible Notes and Options – Balance	Passed	Poll	N/A	36,020,563	76.51%	11,056,528	23.49%	6,004,408	35,570,104	11,056,528	6,004,408	450,459
9	Approval to Issue Performance Rights (NLC)	Passed	Poll	N/A	46,936,208	99.70%	140,849	0.30%	6,004,442	46,485,749	140,849	6,004,442	450,459
10	Approval of 7.1A Mandate	Passed	Poll	N/A	46,928,018	99.70%	141,314	0.30%	6,012,167	46,477,559	141,314	6,012,167	450,459